BridgeBio Oncology Therapeutics, Inc. (BBOT)vsModerna Inc (MRNA)
BBOT
BridgeBio Oncology Therapeutics, Inc.
$3.89
-1.27%
HEALTHCARE · Cap: $319.89M
MRNA
Moderna Inc
$190.01
+0.57%
HEALTHCARE · Cap: $75.86B
Smart Verdict
WallStSmart Research — data-driven comparison
BBOT leads profitability with a 0.0% profit margin vs -141.4%. BBOT earns a higher WallStSmart Score of 31/100 (F).
BBOT
Avoid31
out of 100
Grade: F
MRNA
Avoid21
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for BBOT.
Margin of Safety
+69.9%
Fair Value
$134.59
Current Price
$190.01
$55.42 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Large-cap with strong market position
Conservative balance sheet, low leverage
Areas to Watch
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Trading at 11.2x book value
2.1% revenue growth
Weak financial health signals
ROE of -46.6% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : BBOT
The strongest argument for BBOT centers on Price/Book, Debt/Equity, Altman Z-Score.
Bull Case : MRNA
The strongest argument for MRNA centers on Market Cap, Debt/Equity.
Bear Case : BBOT
The primary concerns for BBOT are Revenue Growth, EPS Growth, Market Cap.
Bear Case : MRNA
The primary concerns for MRNA are Price/Book, Revenue Growth, Piotroski F-Score.
Key Dynamics to Monitor
BBOT profiles as a value stock while MRNA is a turnaround play — different risk/reward profiles.
MRNA carries more volatility with a beta of 1.11 — expect wider price swings.
MRNA is growing revenue faster at 2.1% — sustainability is the question.
BBOT generates stronger free cash flow (-44M), providing more financial flexibility.
Bottom Line
BBOT scores higher overall (31/100 vs 21/100). MRNA offers better value entry with a 69.9% margin of safety. Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
BridgeBio Oncology Therapeutics, Inc.
HEALTHCARE · BIOTECHNOLOGY · USA
BridgeBio Oncology Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of small molecule inhibitor for cancer patients. The company is headquartered in South San Francisco, California.
Moderna Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Moderna, Inc., a biotechnology company, develops messenger RNA-based vaccines and therapies for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and autoimmune diseases. The company is headquartered in Cambridge, Massachusetts.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?